Newsroom | 6417 results

Sorted by: Latest

Neurology
-

Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that management will present at the Piper Sandler 38th Annual Healthcare Conference in New York on Thursday, December 3, 2026 at 9:10 a.m. Eastern Time. Management will also host in-person investor meetings at the conference. A live webcast, as well...
-

Axoft Unveils Meaningful Clinical Momentum of Its Ultra-Soft Fleuron™ Brain Computer Interface Probes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced multiple data milestones from ongoing clinical use of its ultra-soft Fleuron™ Brain Computer Interface (BCI) depth probes at Mass General Brigham (MGB) and The Panama Clinic. Built to leverage the naturally scalable language of the brain, Axoft’s high-density BCIs use the company’s proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material’s supe...
-

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7y...
-

815MNB to Showcase Neuraon Assist Wellness Headband at CES 2027

LAS VEGAS--(BUSINESS WIRE)--815MNB, a South Korean wearable health-tech company, showcases its Neuraon Assist wellness headband at CES 2027....
-

Man & Science voltooit implantatiefase in de ONFIELD First-in-Human-studie naar een geminiaturiseerd ONS-systeem voor chronische clusterhoofdpijn

LUIK--(BUSINESS WIRE)--Man & Science, het Belgische medisch technologiebedrijf gespecialiseerd in geminiaturiseerde neurostimulatie, kondigde vandaag aan dat bij alle tien patiënten in de ONFIELD-pilootstudie bij mensen voor het eerst een implantaat werd geplaatst. Het geminiaturiseerde implantaat voor occipitale zenuwstimulatie (ONS) werd bij hen geactiveerd. De studie richt zich op clusterhoofdpijn en de eerste klinische resultaten zijn bemoedigend. In de ONFIELD-studie worden de veilighe...
-

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache

LIÈGE, Belgium--(BUSINESS WIRE)--Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patient...
-

Man & Science achève l’implantation, dans le cadre de la première étude chez l’homme, ONFIELD, d’un système ONS miniaturisé destiné au traitement des céphalées en grappe chroniques

LIÈGE, Belgique--(BUSINESS WIRE)--Man & Science, une société belge spécialisée dans les dispositifs médicaux et plus particulièrement dans les technologies de neurostimulation miniaturisées, annonce que les dix patients participant à son étude pilote ONFIELD - la première étude chez l’homme - portant sur un implant miniaturisé de stimulation du nerf occipital (ONS) destiné au traitement des céphalées en grappe, ont tous bénéficié de l’implantation et de l’activation de leur dispositif. Les...
-

Man & Science schließt Implantationsphase der ONFIELD-Studie zur erstmaligen Anwendung eines miniaturisierten ONS-Systems bei Patienten mit chronischem Clusterkopfschmerz ab

LÜTTICH, Belgien--(BUSINESS WIRE)--Das belgische Medizintechnikunternehmen Man & Science, das auf miniaturisierte Neurostimulationstechnologien spezialisiert ist, hat die Implantationsphase seiner klinischen ONFIELD-Pilotstudie abgeschlossen. Alle zehn Patienten haben das neu entwickelte Implantat zur Okzipitalnervenstimulation (ONS) zur Behandlung von Clusterkopfschmerz erhalten. Die Systeme wurden bereits aktiviert. Erste klinische Beobachtungen sind vielversprechend. In der ONFIELD-Studi...
-

KeifeRx to Headline Partner Spotlight on Brain Health Innovation at The Third Line Summit, November 19 in Washington, DC

--(BUSINESS WIRE)--KeifeRx: WHAT: A Partner Spotlight conversation, “Advancing Neurodegenerative Disease Treatment: From Discovery to Patient Care,” featuring KeifeRx, a Georgetown University spinout developing disease-modifying medicines for dementia and other neurodegenerative diseases. KeifeRx is a Leadership Partner of the Summit. WHO: Chris Hoyt, CEO & Board Member, KeifeRx, in conversation with Sia Anagnostou, Summit Co-Chair and Head of Programming & Strategic Partnerships, The T...
-

Riassunto: TreeFrog Therapeutics nomina James Sterling Direttore finanziario

BORDEAUX, Francia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--TreeFrog Therapeutics, società biotecnologica che sviluppa terapie cellulari scalabili basate sulla sua tecnologia proprietaria C-Stem™, oggi ha annunciato la nomina di James Sterling all'incarico di Direttore finanziario, a partire dal 1° novembre 2026. James entra a far parte del team dirigente di TreeFrog e riferisce a Mark Rothera, Presidente e Amministratore delegato. Sterling dirige gli aspetti finanziari, le relazioni con gli investi...